Struggling Ohr shutters lab after halting enrollment for PhIII wet AMD study
A few days ago the struggling microcap biotech Ohr Pharmaceutical $OHRP told investors it would “pause” enrollment in their Phase III study of squalimine …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
